within Pharmacolibrary.Drugs.ATC.A;

model A16AX13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.72,
    Cl             = 30 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.0004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00038333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Uridine triacetate is an orally administered prodrug of uridine used as an antidote for overdose or toxic reactions to fluorouracil or capecitabine chemotherapy. It is FDA-approved for emergency treatment within 96 hours of such overdoses or toxicity. Its pharmacological effect relies on increasing uridine levels to counteract toxicity.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adults based on published summaries and secondary references. No detailed PK study found with population or compartmental parameters.</p><h4>References</h4><ol><li><p>Ashour, OM, et al., &amp; el Kouni, MH (2000). Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2&#x27;,3&#x27;,5&#x27;-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy. <i>Cancer chemotherapy and pharmacology</i> 46(3) 235–240. DOI:<a href=&quot;https://doi.org/10.1007/s002800000138&quot;>10.1007/s002800000138</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11021741/&quot;>https://pubmed.ncbi.nlm.nih.gov/11021741</a></p></li><li><p>Kelsen, DP, et al., &amp; Bertino, J (1997). Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 15(4) 1511–1517. DOI:<a href=&quot;https://doi.org/10.1200/JCO.1997.15.4.1511&quot;>10.1200/JCO.1997.15.4.1511</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9193347/&quot;>https://pubmed.ncbi.nlm.nih.gov/9193347</a></p></li><li><p>Hidalgo, M, et al., &amp; Rowinsky, EK (2000). Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 18(1) 167–177. DOI:<a href=&quot;https://doi.org/10.1200/JCO.2000.18.1.167&quot;>10.1200/JCO.2000.18.1.167</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10623707/&quot;>https://pubmed.ncbi.nlm.nih.gov/10623707</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A16AX13;
